

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SinoMab BioScience Limited

中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON 13 JUNE 2022 AND
RETIREMENT OF NON-EXECUTIVE DIRECTOR**

Reference is made to the circular (the “**Circular**”) and the notice of annual general meeting (the “**Notice of 2022 AGM**”) dated 28 April 2022 of SinoMab BioScience Limited (the “**Company**”). Unless the content otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE 2022 AGM

At the 2022 AGM, all the proposed resolutions as set out in the Notice of 2022 AGM were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended 31 December 2021.	167,236,218 (100%)	0 (0%)
2(a).	To re-elect Mr. Ping Cho Terence HON as an independent non-executive director of the Company.	167,236,218 (100%)	0 (0%)
2(b).	To re-elect Dr. Shui On LEUNG as an executive director of the Company.	167,236,218 (100%)	0 (0%)
2(c).	To re-elect Ms. Wenyi LIU as a non-executive director of the Company.	167,236,218 (100%)	0 (0%)
2(d).	To re-elect Dr. Chi Ming LEE as an independent non-executive director of the Company.	167,236,218 (100%)	0 (0%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
2(e).	To re-elect Ms. Jie LIU as a non-executive director of the Company.	167,236,218 (100%)	0 (0%)
2(f).	To re-elect Mr. Lei SHI as a non-executive director of the Company.	167,236,218 (100%)	0 (0%)
2(g).	To authorise the board of directors to fix the respective directors' remuneration.	167,236,218 (100%)	0 (0%)
3.	To re-appoint Ernst & Young as auditor of the Company and to authorise the board of directors to fix their remuneration.	167,236,218 (100%)	0 (0%)
4.	To give a general mandate to the directors of the Company to buy back shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of the passing of this resolution.	167,236,218 (100%)	0 (0%)
5.	To give a general mandate to the directors of the Company to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of the passing of this resolution.	167,236,218 (100%)	0 (0%)
6.	To extend the general mandate granted to the directors of the Company to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares bought back by the Company under the general mandate in Resolution (4).	167,236,218 (100%)	0 (0%)

Notes:

- (a) As all of the votes were cast in favour of each of the resolutions numbered 1 to 6, all resolutions were duly passed as ordinary resolutions.
- (b) As at the date of the 2022 AGM, the total number of shares of the Company in issue was 1,006,240,400 shares.
- (c) The total number of shares of the Company entitling the holders to attend and vote on all the resolutions at the 2022 AGM was 1,006,240,400 shares.
- (d) There were no shares entitling the holders to attend and abstain from voting in favour of any of the resolutions at the 2022 AGM as set out in rule 13.40 of the Listing Rules.
- (e) None of the shareholders of the Company were required under the Listing Rules to abstain from voting on the resolutions at the 2022 AGM.

- (f) None of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the 2022 AGM.
- (g) The Company's share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the poll taken at the 2022 AGM.
- (h) All directors of the Company, attended the 2022 AGM in person or by electronic means.

RETIREMENT OF NON-EXECUTIVE DIRECTOR

The Board announces that Mr. Senlin LIU (“**Mr. Liu**”), a non-executive Director, retired from office by rotation and did not offer himself for re-election at the 2022 AGM for the purpose of devoting more time to his personal business engagement. Mr. Liu retired as a non-executive Director of the Company with effect from the conclusion of the 2022 AGM.

Mr. Liu has confirmed that he has no disagreement with the Board and there are no matters that need to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its gratitude to Mr. Liu for his valuable contributions and support during his tenure.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 13 June 2022

Following the conclusion of the 2022 AGM, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Dr. Haigang CHEN, Mr. Xun DONG, Ms. Wenyi LIU, Ms. Jie LIU and Mr. Lei SHI, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.